StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
PALIBullishIndustry Newsnews
High materiality8/10

Palisade Bio's PALI-2108 shows early promise; IND in 2026 could unlock value

Jul 23, 2026, 2:26 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

News signals pipeline progress and favorable long-term sales potential; immediate price move reflects momentum rather than cash flow.

AI summary

What happened, with direct paths to the underlying reporting

PALI-2108 is an intestine-activated PDE4 inhibitor prodrug with positive Phase 1 data, and Palisade plans a Phase 2 IND for ASCENTRA-CD in 2H 2026. Oppenheimer projects long-term peak U.S. sales of $2.6B in UC (2040) and $2.8B in fibrostenotic CD (2041); a Buy on PALI supports a multi-year re-rating if Phase 2 data align with early signals. Near-term moves may reflect momentum around IND timing and trial progress.

  • PALI-2108 is an intestine-activated PDE4 prodrug with Phase 1 gains.
  • IND submission for Phase 2 ASCENTRA-CD targeted in 2H 2026.
  • Analysts set Buy rating; price target around $8.
  • Stock rose about 12% to $2.13 on news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event